A Prognostic Tool for COVID-19 Decision Support: The Intermountain Risk Score Predicts Major Adverse Health Events in Patients Positive for COVID-19

2021 ◽  
Author(s):  
Benjamin D. Horne ◽  
Joseph R. Bledsoe ◽  
Joseph B. Muhlestein ◽  
Heidi T. May ◽  
Ithan D. Peltan ◽  
...  
NEJM Evidence ◽  
2021 ◽  
Author(s):  
Michael Furian ◽  
Maamed Mademilov ◽  
Aline Buergin ◽  
Philipp M. Scheiwiller ◽  
Laura Mayer ◽  
...  

Furian and colleagues report on the results of two randomized controlled trials testing the use of acetazolamide to prevent the adverse effects of altitude on healthy older persons and in people with COPD. They find that acetazolamide decreased the incidence of altitude related adverse health events (primarily hypoxemia) in both populations with no evidence of adverse events.


2008 ◽  
Vol 24 (04) ◽  
pp. 430-436 ◽  
Author(s):  
David Hailey ◽  
Philip D. Jacobs ◽  
Nola M. Ries ◽  
Julie Polisena

Objectives:The aim of this study was to assess the evidence that reuse of medical devices marketed for single use only (SUDs) is safe, effective and cost-effective, and to consider the use and health services impact of this practice in Canada.Methods:A systematic review was performed of studies that reported clinical or economic outcomes following reuse of SUDs in humans. Direct costs of adverse health events associated with SUD reuse and indications of budget impact were obtained using data for devices for laparoscopic cholecystectomy and coronary angioplasty. Legal and ethical issues were reviewed, drawing on material relevant to Canada. Data on current reuse of SUDs were obtained through a survey of Canadian acute care hospitals.Results:Studies of variable quality suggested that SUD reuse could be safe and effective, and would give cost savings, if there were no adverse events. Eliminating reuse of SUDs for laparoscopic cholecystectomy and coronary angioplasty would add less than 0.1 percent to costs of the procedures over 1 year. Adverse health events associated with device reuse create liability risks; patients should be informed of any known or foreseeable risks of reuse. Most of the 28 percent (111/398) of acute hospitals that reprocess SUDs do so in-house. Some do not have a written policy or an incident reporting mechanism.Conclusions:There is insufficient evidence to establish the safety, efficacy and cost-effectiveness of reusing SUDs. Legal and ethical issues require attention to minimize liability and maintain patient safety and trust. Some hospitals that reprocess SUDs do not have adequate documentation. These findings do not support the reuse of SUDs in Canadian hospitals.


2015 ◽  
Vol 50 (6) ◽  
pp. 850-857 ◽  
Author(s):  
M Wilhelmsson ◽  
A Vatanen ◽  
B Borgström ◽  
B Gustafsson ◽  
M Taskinen ◽  
...  

Midwifery ◽  
2012 ◽  
Vol 28 (4) ◽  
pp. 416-421 ◽  
Author(s):  
Celene Aparecida Ferrari Audi ◽  
Ana M. Segall-Corrêa ◽  
Silvia M. Santiago ◽  
Rafael Pérez-Escamilla

Drugs & Aging ◽  
2017 ◽  
Vol 34 (5) ◽  
pp. 359-365 ◽  
Author(s):  
Médéa Locquet ◽  
Germain Honvo ◽  
Véronique Rabenda ◽  
Thierry Van Hees ◽  
Jean Petermans ◽  
...  

2017 ◽  
Vol 45 (12) ◽  
pp. 2279-2294 ◽  
Author(s):  
Guy Cafri ◽  
Luo Li ◽  
Elizabeth W. Paxton ◽  
Juanjuan Fan

Sign in / Sign up

Export Citation Format

Share Document